Obio Pharmaceutical Holdings Limited ' Product Pipeline Review ' 2012 Summary Global Markets Direct's pharmaceuticals report, 'Obio Pharmaceutical Holdings Limited - Product Pipeline Review - 2012' provides data on the Obio Pharmaceutical Holdings Limited's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct's proprietary databases, Obio Pharmaceutical Holdings Limited's corporate website, SEC filings, investor presentations and featured press releases, both from Obio Pharmaceutical Holdings Limited and industry-specific third party sources, put together by Global Markets Direct's team. Scope - Obio Pharmaceutical Holdings Limited - Brief Obio Pharmaceutical Holdings Limited overview including business description, key information and facts, and its locations and subsidiaries.- Review of current pipeline of Obio Pharmaceutical Holdings Limited human therapeutic division.- Overview of pipeline therapeutics across various therapy areas.- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.- Product profiles for late stage and clinical stage products of Obio Pharmaceutical Holdings Limited with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Obio Pharmaceutical Holdings Limited's pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products. Reasons to buy - Evaluate Obio Pharmaceutical Holdings Limited's strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Obio Pharmaceutical Holdings Limited in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Obio Pharmaceutical Holdings Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. - Exploit collaboration and partnership opportunities with Obio Pharmaceutical Holdings Limited. - Avoid Intellectual Property Rights related issues. - Explore the dormant and discontinued projects of Obio Pharmaceutical Holdings Limited and identify potential opportunities in those areas.

1. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Obio Pharmaceutical Holdings Limited ' Product Pipeline Review '
2012
Published on August 2012
Report Summary
Obio Pharmaceutical Holdings Limited ' Product Pipeline Review ' 2012
Summary
Global Markets Direct's pharmaceuticals report, 'Obio Pharmaceutical Holdings Limited - Product Pipeline Review - 2012' provides
data on the Obio Pharmaceutical Holdings Limited's research and development focus. The report includes information on current
developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct's proprietary databases, Obio Pharmaceutical
Holdings Limited's corporate website, SEC filings, investor presentations and featured press releases, both from Obio Pharmaceutical
Holdings Limited and industry-specific third party sources, put together by Global Markets Direct's team.
Scope
- Obio Pharmaceutical Holdings Limited - Brief Obio Pharmaceutical Holdings Limited overview including business description, key
information and facts, and its locations and subsidiaries.
- Review of current pipeline of Obio Pharmaceutical Holdings Limited human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities,
across the globe.
- Product profiles for late stage and clinical stage products of Obio Pharmaceutical Holdings Limited with complete description of the
product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Obio Pharmaceutical Holdings Limited's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Obio Pharmaceutical Holdings Limited's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Obio Pharmaceutical Holdings Limited in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Obio Pharmaceutical Holdings Limited's R&D portfolio and develop key
strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Obio Pharmaceutical Holdings Limited.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Obio Pharmaceutical Holdings Limited and identify potential opportunities in those
areas.
Obio Pharmaceutical Holdings Limited ' Product Pipeline Review ' 2012 (From Slideshare) Page 1/5

2. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Table of Content
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Obio Pharmaceutical Holdings Limited Snapshot 4
Obio Pharmaceutical Holdings Limited Overview 4
Key Information 4
Key Facts 4
Obio Pharmaceutical Holdings Limited ' Research and Development Overview 5
Key Therapeutic Areas 5
Obio Pharmaceutical Holdings Limited ' Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products ' Monotherapy 8
Obio Pharmaceutical Holdings Limited ' Pipeline Products Glance 9
Obio Pharmaceutical Holdings Limited Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
Phase I Products/Combination Treatment Modalities 10
Obio Pharmaceutical Holdings Limited ' Early Stage Pipeline Products 11
Pre-Clinical Products/Combination Treatment Modalities 11
Obio Pharmaceutical Holdings Limited ' Drug Profiles 12
AK20 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
DC9703 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
KP624 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
KP9928 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
PK236 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
TG21 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Obio Pharmaceutical Holdings Limited ' Product Pipeline Review ' 2012 (From Slideshare) Page 2/5

3. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Obio Pharmaceutical Holdings Limited ' Pipeline Analysis 18
Obio Pharmaceutical Holdings Limited ' Pipeline Products by Therapeutic Class 18
Obio Pharmaceutical Holdings Limited ' Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Appendix 20
Methodology 20
Coverage 20
Secondary Research 20
Primary Research 20
Expert Panel Validation 20
Contact Us 21
Disclaimer 21
List of Tables
Obio Pharmaceutical Holdings Limited, Key Information 4
Obio Pharmaceutical Holdings Limited, Key Facts 4
Obio Pharmaceutical Holdings Limited ' Pipeline by Indication, 2012 6
Obio Pharmaceutical Holdings Limited ' Pipeline by Stage of Development, 2012 7
Obio Pharmaceutical Holdings Limited ' Monotherapy Products in Pipeline, 2012 8
Obio Pharmaceutical Holdings Limited ' Phase II, 2012 9
Obio Pharmaceutical Holdings Limited ' Phase I, 2012 10
Obio Pharmaceutical Holdings Limited ' Pre-Clinical, 2012 11
Obio Pharmaceutical Holdings Limited ' Pipeline By Therapeutic Class, 2012 18
Obio Pharmaceutical Holdings Limited, Other Locations 19
List of Figures
Obio Pharmaceutical Holdings Limited ' Pipeline by Indication, 2012 6
Obio Pharmaceutical Holdings Limited ' Pipeline by Stage of Development, 2012 7
Obio Pharmaceutical Holdings Limited ' Monotherapy Products in Pipeline, 2012 8
Obio Pharmaceutical Holdings Limited ' Product Pipeline Review ' 2012 (From Slideshare) Page 3/5

4. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
Obio Pharmaceutical Holdings Limited ' Product Pipeline Review ' 2012
Product Formats
Please select the product formats and the quantity you require.
1 User License--USD 1 500.00 Quantity: _____
Site License--USD 3 000.00 Quantity: _____
Corporate License--USD 4 500.00 Quantity: _____
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
Obio Pharmaceutical Holdings Limited ' Product Pipeline Review ' 2012 (From Slideshare) Page 4/5

5. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
Obio Pharmaceutical Holdings Limited ' Product Pipeline Review ' 2012 (From Slideshare) Page 5/5